Effective immediately, due to low test utilization and the high cost of maintaining proficiency, the following FISH tests will no longer be offered:
• Prader-Willi/Angelman (15q11-q13) by FISH
Recommended test is Angelman/Prader-Willi mPCR
• Smith Magenis (17p11) by FISH
• Williams (7q11,23) by FISH
If need arises for this test, please place an order for a Send out Genetics Miscellaneous and enter requested test in the comments. The testing will be sent out through Spectrum Health.
Any questions about referral testing may be directed to the Referral Department. Any questions or concerns regarding these changes may be directed to Dr. Salah Ebrahim in the Cytogenetics Laboratory.
Effective immediately, due to low test utilization and the high cost of maintaining proficiency, the Chromosome Analysis Breakage Study will no longer be offered by the Spectrum Health Cytogenetics Department.
If need arises for this test, please place an order for a Reference Miscellaneous (EPIC# LAB848) and enter “Test 140 DEB Breakage Study to Integrated Genetics” in the comments. The testing will be sent out through Spectrum Health Referrals Department to Integrated Genetics.
Effective May 20, 2019, Spectrum Health Regional Laboratory Cytogenetics Department is pleased to announce the launch of a new microarray platform AffymetrixTM Cytoscan® HD. The Affymetrix Cytoscan HD is designed for the accurate and comprehensive analysis of chromosomal variants in the human genome.
Spectrum Health Regional Laboratory (SHRL) was featured on EightWest on WOOD TV8 on Tuesday, August 30, 2016. Dr. Stephanie F. Williams, Division Chief of Spectrum Health Adult Bone and Marrow Transplant, and Kim Collison, Director of Laboratory Services, talk about the importance and benefits of having SHRL’s Advanced Technology Laboratory right here in West Michigan.
The Advanced Technology Laboratory is “extremely important, particularly for patients with certain cancers…”
“It helps us to diagnose the patients faster and more accurately; to follow the progress of their disease during the treatments that we give, and even at times to guide us in what is the best treatment for a patient…”
“Within 2 hours we had the answer. We did not have to send that specimen out to another laboratory in another state.”
-Stephanie F. Williams, MD, Division Chief, Spectrum Health Adult Bone and Marrow Transplant
The treatment of non-small cell lung adenocarcinoma has become more successful due to targeted treatments based on the molecular profile of a patient’s particular tumor. The Lung Cancer Mutation Analysis panel is now available for clinical testing at the Spectrum Health Advanced Technology Laboratories (ATL).